We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

BEAMing Technology Effectively Detects Cancer-Linked Mutations in Liquid Biopsy Samples

By LabMedica International staff writers
Posted on 19 Jul 2015
Print article
Image: The principle of blood-based DNA testing (Photo courtesy of Sysmex-Inostics).
Image: The principle of blood-based DNA testing (Photo courtesy of Sysmex-Inostics).
Liquid biopsy using BEAMing technology was found to be an effective method for analyzing tumor genotypes in real time and identifying significant mutations that occur during the course of disease and are not detected by tissue biopsy.

Rapid developments in the technology and protocols required for reliably isolating and analyzing circulating tumor DNA (ctDNA) in peripheral blood are making it easier to obtain the necessary samples without the need for physical biopsies. One such method, developed by Sysmex-Inostics (Kobe, Japan), utilizes digital PCR to detect somatic tumor mutations in ctDNA with high sensitivity. The technique combines emulsion digital PCR and flow cytometry. Known as BEAMing, it employs a combination of beads, emulsification, amplification, and magnetics to achieve the necessary level of sensitivity.

The BEAMing process starts with isolating and purifying the DNA present in blood plasma, which then goes through a pre-amplification step using conventional PCR to amplify the genetic section of interest using primers incorporating known tag sequences. These DNA templates are then amplified again via emulsion PCR, employing primers directed at these sequence tags and covalently bound to magnetic microbeads via streptavidin–biotin interactions. By designing the system this way, the PCR products generated in each emulsion droplet will remain physically affixed to the microbeads at the end of the reaction, allowing them to be easily separated and purified using a magnet. The method also provides a digital readout of copy number, as it has been experimentally optimized to ensure that each emulsion droplet will contain a maximum of one microbead and one DNA template molecule. This makes it possible to detect even very rare mutant templates at copy ratios greater than 1:10,000.

BEAMing technology was used to analyze the DNA in 503 blood samples acquired from patients with metastatic colorectal cancer participating in the CORRECT (previously treated metastatic colorectal cancer) phase III trial.

Results revealed that tumor-associated mutations could readily be detected by BEAMing of plasma DNA, with KRAS mutations identified in 69% of patients, PIK3CA mutations in 17% of patients, and BRAF mutations in 3% of patients. The results also showed that the drug regorafenib seemed to be consistently associated with a clinical benefit in a range of patient subgroups based on mutational status and protein biomarker concentrations.

Regorafenib (commercial name Stivarga) is an oral multi-kinase inhibitor, which targets angiogenic, stromal, and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows antiangiogenic activity due to its dual targeted VEGFR2-TIE2 (vascular endothelial growth factor receptor 2 - tyrosine kinase with immunoglobulin-like and EGF-like domains 2) tyrosine kinase inhibition. Regorafenib has been shown to increase the overall survival of patients with metastatic colorectal cancer and is currently being studied as a potential treatment option in multiple tumor types.

"This is the first large clinical trial to compare liquid versus conventional tissue biopsy data, and the results show the former (BEAMing technology) obtain more data on tumor mutation throughout the course of the disease, enabling us to better target therapy to the specificities of patient's tumor; this could have a considerable impact on clinical practice, as novel applications of this technology could be further investigated and developed," said first author Dr. Josep Tabernero, head of the medical oncology department at the Vall d'Hebron Institute of Oncology (Barcelona, Spain).

The CORRECT BEAMing study was published in the July 13, 2015, online edition of the journal the Lancet Oncology.

Related Links:

Vall d'Hebron Institute of Oncology

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
Blood Ammonia Test Analyzer
Vortex Mixer
Colorimetric Assay
MYCOFAST RevolutioN 2

Print article


Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Molecular Diagnostics

view channel
Image: The ClarityDX Prostate test can reduce unnecessary prostate biopsies by up to 35% (Photo courtesy of Nanostics)

Innovative Blood Test to Revolutionize Prostate Cancer Detection and Reduce Invasive Biopsies

One in six men will receive a prostate cancer diagnosis during their lives. Thankfully, if caught early, prostate cancer is highly treatable. However, the existing screening process has its limitations.... Read more


view channel
Image: The latest FDA clearance has finally brought HemoScreen to its full potential as a true POC hematology analyzer (Photo courtesy of PixCell)

True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

An innovative 5-part differential Complete Blood Count (CBC) analyzer with direct capillary sampling capability significantly simplifies blood sampling and minimizes the pre-analytical process.... Read more


view channel
Image: A new test could detect the body’s adaptive immune response to viruses (Photo courtesy of 123RF)

Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form

The adaptive immune system is an incredible defense mechanism that allows the human body to identify and mount targeted responses against specific pathogens. T-Cells, a special kind of white blood cell,... Read more


view channel
Image: On-chip pretreatment and rapid AST based directly on positive blood cultures (Photo courtesy of Liu Yang)

Integrated Solution for Rapid AST Directly From Positive Blood Cultures to Combat Bloodstream Infection

The presence of living bacteria in the bloodstream, known as bacteremia, can lead to serious conditions like bloodstream infections (BSIs) and sepsis, which can often be fatal. Quickly prescribing the... Read more


view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more


view channel
Image: AACC Middle East is a two-day conference that brings the latest in laboratory medicine to the Middle East region (Photo courtesy of ADLM)

AACC Middle East 2023 to Explore Latest Trends in Clinical Pathology and Laboratory Medicine

The AACC Middle East Conference and Exposition will be held by the Association for Diagnostics & Laboratory Medicine (ADLM - formerly AACC, Washington, DC, USA) in partnership with Life Dx (Abu Dhabi,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.